Public interest group accuses FDA of trying to discredit whistleblower

BMJ 2004; 329 doi: 10.1136/bmj.329.7477.1255-a (Published 25 November 2004)
Cite this as: BMJ 2004;329:1255.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeanne Lenzer
  1. New York

    A public interest group that aims to protect whistleblowers claimed last week that an attempt had been made by a member of staff at the Food and Drug Administration to discredit Dr David Graham, the FDA executive who testified to the US Senate committee on 18 November.

    Dr Graham, associate director in the FDA's Office of Drug Safety, had carried out a study with Kaiser Permanente of northern California that looked …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL